





































































































（tumor volume doubling time: Td）、SI ratio（SIR） 
on the MRI T2 weighted images、病理組織所見、



















腫 瘍 面 積 の 最 も 広 いaxialス ラ イ ス のT2 signal 
intensityの腫瘍平均値と水晶体の平均値の比を算出し
た。
all II III IV
number of cases 104 53 14 37
age 56.5±12.0 60±11.7 51±12.7 53±13.2
sex (male/female) 28/76 11/42 5/9 12/25
volume fo tumor(cm3) 17.4±22.8 17.4±24.7 15.9±22.9 18±26.1





































ると、前頭蓋底ではtuberculum sellae 12例、olfactory 
groove ８例、optic sheath ４例、others １例、中頭蓋
底ではsphenoid ridge 29例、plamum sphenoidale ４例、
cavernous sinus ４例、others １例、後頭蓋底では
















total II III IV
Case No. 104 53 14 37
tumor location
Anterior fossa 25 17 4 4
olfactory groove 12 9 1 2 (1)
tuberculum sellae 8 7 1 0
optic sheath 4 0 2 2
others 1 1 0 0
Middle fossa 38 21 3 14 
sphenoid ridge 29 17 2 10 (3)
plamnum 
sphenoidale
4 3 1 0
cavernous sinus 4 0 0 4 (4)
others 1 1 0 0
Posterior fossa 41 15 7 19
tentrial 17 6 5 6 (3)
petrous 11 7 2 2
petroclival 10 1 0 9 (5)
juglar foramen 1 0 0 1 (1)
































内 訳 はmeningothelial 58例、fibrous 18例、transitional 

































































































































Odds ratio 95％CI p value
age 1.009 0.950-1.071 0.778
sex 0.697 0.145-3.346 0.652
Regidual volume 2.353 1.199-4.617 0.013*
MIB-LI 1.253 1.027-1.530 0.027*
T2SI 1380.321 4.304-442632.493 0.014*
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Background: Function-preserving total resection of skull base meningioma（SBM）is not always 
possible due to important neighboring structures, and life-threatening complications of SBM are not 
acceptable due to benignity.  In our department, although we have performed gross total resection, 
we have used stereotactic radiotherapy（≤1 year）for intentionally keeping tumors at high risk for 
potential complications.  Based on our 20-year accumulated data on this therapeutic strategy, this 
study aimed to establish treatment guidelines for SBM. 
Subjects and Methods: 104 patients with SBM who underwent resection from April 1994 to April 
2013 participated in this study［S group（resection alone）: n=87; eRT group（adjuvant radiotherapy 
for remaining tumor）: n=17］.  Examination items included tumor enlargement, doubling time, 
magnetic resonance T2 image signal intensity ratio（T2-SIR）, pathologic findings, Simpson grade, 
MIB-1 labeling index（LI）, and radiotherapy. 
Results: In Simpson grade IV, tumor control probabilities in the S group［70.7%（5-year）, 56.6%（10-
year）］were significantly lower in the eRT group［93.3%（5-year）, 81.7%（10-year）］. Mortality（0.0%）
and morbidity（4.8%）showed good outcomes. Significant factors for tumor enlargement were MIB-1 
LI, remaining tumor volume, and T2-SIR.
Conclusions: Our treatment guidelines for SBM were beneficial.  It is important to treat and monitor 
SBM patients based on biological tumor characteristics elucidated by this study. 
Key words: Meningioma, Skull base, Stereotactic radiotherapy, Remaining tumor volume, Tumor 
  control probability
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